ACADIA Pharmaceuticals (NASDAQ:ACAD) and Milestone Pharmaceuticals (NASDAQ:MIST) Head-To-Head Contrast

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Milestone Pharmaceuticals (NASDAQ:MIST) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Institutional & Insider Ownership

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 19.5% of Milestone Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares ACADIA Pharmaceuticals and Milestone Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07 billion	3.46	$391.00 million	$2.20	9.83
Milestone Pharmaceuticals	$1.55 million	115.66	-$63.06 million	($0.68)	-2.12

ACADIA Pharmaceuticals has higher revenue and earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for ACADIA Pharmaceuticals and Milestone Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	1	3	11	1	2.75
Milestone Pharmaceuticals	2	0	3	1	2.50

ACADIA Pharmaceuticals presently has a consensus price target of $31.63, indicating a potential upside of 46.21%. Milestone Pharmaceuticals has a consensus price target of $7.25, indicating a potential upside of 403.47%. Given Milestone Pharmaceuticals’ higher possible upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than ACADIA Pharmaceuticals.

Volatility and Risk

ACADIA Pharmaceuticals has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.

Profitability

This table compares ACADIA Pharmaceuticals and Milestone Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%

Summary

ACADIA Pharmaceuticals beats Milestone Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.